Erythromycin Ethylsuccinate Tablets

This product belongs to the macrolide antibiotics, which is the ethyl succinate of erythromycin. It is more stable than erythromycin in gastric acid. It has antibacterial activity against Staphylococcus (except methicillin-resistant strains), all groups of streptococci and Gram-positive bacilli. Neisseria, Haemophilus influenzae, Bordetella pertussis, etc. are also sensitive to this product. This product also has antibacterial effects on various anaerobic bacteria except Bacteroides fragilis and Fusobacterium. It also has inhibitory effects on Legionella, Campylobacter fetus, some spirochetes, Mycoplasma pneumoniae, Rickettsia, Chlamydia and Chlamydia. This product is an antibacterial agent, but it also has a bactericidal effect on some bacteria at high concentrations. This product can penetrate the bacterial cell membrane and form a reversible combination with the 50S subunit of the bacterial ribosome near the donor site (P site), blocking the transfer RNA (t-RNA) from binding to the P site, and also blocking the displacement of the polypeptide chain from the acceptor site (A site) to the P site, thereby inhibiting bacterial protein synthesis.

Erythromycin ethylsuccinate.

This product is white tablets.

1. This product can be used as an alternative to penicillin-allergic patients to treat the following infections: acute tonsillitis, acute pharyngitis, sinusitis caused by hemolytic streptococci, pneumococcus, etc.; scarlet fever and cellulitis caused by hemolytic streptococci; diphtheria and diphtheria carriers; gas gangrene, anthrax, tetanus, and legionnaires' disease. 3. Mycoplasma pneumonia. 4. Chlamydia pneumoniae pneumonia. 5. Urinary and reproductive system infections caused by Chlamydia and Mycoplasma. 6. Chlamydia trachomatis conjunctivitis. 7. Oral infections caused by anaerobic bacteria. 8. Campylobacter jejuni enteritis. 9. Whooping cough. 10. Relapse of rheumatic fever, infective endocarditis (after rheumatic heart disease, congenital heart disease, heart valve replacement surgery) and preventive medication during oral and upper respiratory tract medical operations (alternative to penicillin).

Oral administration: adults 1.6g per day, divided into 2 to 4 doses.

1. Patients with hepatotoxic reactions after taking this product are more common than those taking other erythromycin preparations. After taking the drug for several days or 1 to 2 weeks, patients may experience fatigue, nausea, vomiting, abdominal pain, rash, fever, etc. Jaundice may sometimes occur, and liver function tests show cholestasis, which can often be recovered after stopping the drug. 2. Gastrointestinal reactions include diarrhea, nausea, vomiting, upper abdominal pain, mouth and tongue pain, decreased appetite, etc., and their incidence is related to the size of the dose. 3. When a large dose of 〈ge;4g/day〉 is used, especially in patients with liver and kidney diseases or elderly patients, hearing loss may occur, which is mainly related to the high blood drug concentration (12mg/L), and most of them can be recovered after stopping the drug. 4. Allergic reactions are manifested as drug fever, rash, eosinophilia, etc., with an incidence of about 0.5% to 1%. 5. Others, occasionally arrhythmias, oral or vaginal candidal infections.

It is contraindicated for patients who are allergic to this product or other erythromycin preparations, patients with chronic liver disease, patients with liver damage and pregnant women.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: 1. Due to the increased possibility of hepatotoxicity, it is forbidden for pregnant women. 2. Since a considerable amount of this product enters breast milk, lactating women should use it with caution or stop breastfeeding. Precautions for the elderly: Not yet clear.

1. This product can inhibit the metabolism of anti-epileptic drugs such as carbamazepine and valproic acid, resulting in increased blood concentrations and toxic reactions. Combination with fentanyl can inhibit the metabolism of the latter and prolong its duration of action. Combination with antihistamines such as astemizole or terfenadine can increase cardiac toxicity, and combination with cyclosporine can increase the latter's blood concentration and produce nephrotoxicity. 2. This product has an antagonistic effect with chloramphenicol and lincosamides, and it is not recommended to use them at the same time. 3. This product is an antibacterial agent and can interfere with the bactericidal efficacy of penicillin. Therefore, when rapid bactericidal effects are required, such as the treatment of meningitis, the two should not be used at the same time. 4. Patients who take warfarin for a long time can prolong the prothrombin time when using this product, thereby increasing the risk of bleeding. Elderly patients should pay special attention. When the two must be used at the same time, the dose of warfarin should be appropriately adjusted and the prothrombin time should be closely observed. 5Except for dihydroxypropylphylline, the simultaneous use of this product with xanthine drugs can reduce the hepatic clearance of aminophylline, leading to increased serum aminophylline concentrations and (or) increased toxic reactions. This phenomenon is more likely to occur after 6 days of combined use, and the reduction in aminophylline clearance is proportional to the serum peak value of this product. Therefore, the dose of xanthine drugs should be adjusted during and after the combination of the two. 6This product may enhance hepatotoxicity when used in combination with other hepatotoxic drugs. 7The combination of large doses of this product with ototoxic drugs, especially in patients with renal impairment, may increase ototoxicity. 8When used in combination with lovastatin, its metabolism can be inhibited and blood concentrations can be increased, which may cause rhabdomyolysis; when used in combination with midazolam or triazolam, the clearance of both can be reduced and their effects can be enhanced.

Keep sealed.

0.1g (100,000 units) based on C37H67NO13

36 months.

Shanghai Tengrui Pharmaceutical Co., Ltd.

• Founded in:

  2010-09-27

• Address:

  No. 151, Lane 1236, Xinsiping Road, Shituan Town, Fengxian District, Shanghai

• Tax NO.:

  91310120563054643T

• Registered Funds:

  223.274424 yuan

• Website:

  Log in to view

• Email:

  Log in to view